TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

ETAS ID: TM822119

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Valo Health, Inc.		06/30/2023	Corporation: DELAWARE

RECEIVING PARTY DATA

Name:	FIRST-CITIZENS BANK & TRUST COMPANY, AS AGENT
Street Address:	505 Howard Street
Internal Address:	Floor 3
City:	San Francisco
State/Country:	CALIFORNIA
Postal Code:	94105
Entity Type:	Corporation: NORTH CAROLINA

PROPERTY NUMBERS Total: 2

Property Type	Number	Word Mark
Registration Number:	6486701	BIOWIRE
Registration Number:	3660448	NUMERATE

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (619) 699-2708

Email: christian.cruz@us.dlapiper.com

Correspondent Name: DLA Piper LLP (US) Address Line 1: 4365 Executive Drive

Address Line 2: **Suite 1100**

Address Line 4: San Diego, CALIFORNIA 92121

NAME OF SUBMITTER:	Matt Schwartz
SIGNATURE:	/s/ Matt Schwartz
DATE SIGNED:	07/05/2023

Total Attachments: 11

source=SVB-Valo Health- Amended and Restated IPSA (6.2023)#page1.tif source=SVB-Valo Health- Amended and Restated IPSA (6.2023)#page2.tif source=SVB-Valo Health- Amended and Restated IPSA (6.2023)#page3.tif



AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Amended and Restated Intellectual Property Security Agreement ("this Agreement") dated as of June 30, 2023 is made by and among (a) SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)) ("SVB"), in its capacity as administrative agent and collateral agent (in such capacity, "Agent"), (b) VALO HEALTH, LLC, a Delaware limited liability company (f/k/a INTEGRAL HEALTH HOLDINGS, LLC) ("Parent"), as a Guarantor, and (c) VALO HEALTH, INC., a Delaware corporation (f/k/a INTEGRAL HEALTH, INC.) ("Opco") (Parent, Opco and each such Qualified Subsidiary, individually and collectively, jointly and severally, "Grantor") in connection with (x) that certain Loan and Security Agreement dated as of June 15, 2020 (as the same may be amended, modified or supplemented from time to time, including without limitation by that certain First Amendment to Loan and Security Agreement dated as of December 7, 2020, that certain Consent and Second Amendment to Loan and Security Agreement dated as of December 31, 2020, that certain Third Amendment to Loan and Security Agreement dated as of February 1, 2021, that certain Fourth Amendment to Loan and Security Agreement dated as of February 19, 2021, and that certain Default Waiver and Fifth Amendment to Loan and Security Agreement dated as of the date hereof, collectively, the "Loan Agreement") by and among Grantor, Agent, SVB in its capacity as a Lender, and HERCULES CAPITAL, INC., a Maryland corporation in its capacity as a Lender thereunder ("Hercules" and together with SVB, the "Lenders"), and (ii) that certain Unconditional Secured Guaranty and Pledge Agreement dated as of June 15, 2020 (as the same may be amended, modified or supplemented from time to time, the "Parent Guaranty") entered into by Parent in favor of Agent and the Lenders. This Agreement amends, restates, and supersedes in its entirety (a) that certain Intellectual Property Security Agreement dated as of June 15, 2020 by and between Parent and Agent, and (b) that certain Intellectual Property Security Agreement dated as of June 15, 2020 by and between Opco and Agent. Capitalized terms used but not defined herein, shall bear the meanings ascribed to such terms in the Loan Agreement.

RECITALS

- A. The Lenders are willing to make loans to Borrower, but only upon the condition, among others, that Grantor shall grant to Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the Obligations of Grantor.
- B. Pursuant to the terms of the Loan Agreement and the Parent Guaranty, Grantor has granted to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.
- NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of Grantor's Obligations, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. <u>Grant of Security Interest</u>. To secure Grantor's Obligations, Grantor grants and pledges to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under its Intellectual Property (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:

1

- (a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");
- (b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;
- (c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;
- (d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, now or hereafter existing, created, acquired or held, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");
- (e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit B attached hereto (collectively, the "Trademarks");
- (f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on <u>Exhibit C</u> attached hereto (collectively, the "Mask Works");
- (g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;
- (h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;
- (i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and
- (j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding anything to the contrary herein, the Intellectual Property Collateral shall not include any Intellectual Property associated with clinical and preclinical therapeutic assets of any Loan Party ("Excluded Intellectual Property"); provided, however, the Collateral shall include all Accounts and all proceeds of all Intellectual Property (including the Excluded Intellectual Property). If a judicial authority (including a U.S. Bankruptcy Court) would hold that a security interest in the underlying Intellectual Property is necessary to have a security interest in such Accounts and such property that are proceeds of Intellectual Property, then the Collateral shall automatically, and effective as of the Effective Date, include the Excluded Intellectual Property to the extent necessary to permit perfection of Agent's, for the ratable benefit of the Lenders, security interest in such Accounts and such other property of the Loan Parties that are proceeds of such Intellectual Property.

2

- 2. <u>Recordation</u>. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Agent.
- 3. <u>Authorization</u>. Grantor hereby authorizes Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement, and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.
- 4. <u>Loan Documents.</u> This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement and the Parent Guaranty, which are hereby incorporated by reference. The provisions of the Loan Agreement and the Parent Guaranty shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Agent with respect to the Intellectual Property Collateral are as provided by the Loan Agreement, Parent Guaranty, and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.
- 5. <u>Execution in Counterparts</u>. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., "pdf" or "tif" format) shall be effective as delivery of a manually executed counterpart of this Agreement.
- 6. <u>Successors and Assigns</u>. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.
- 7. <u>Governing Law.</u> This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United States and the State of California, without giving effect to any choice or conflict of law provision or rule (whether of the State of California or any other jurisdiction).

[Balance of Page Intentionally Left Blank]

3

IN WITNESS WHEREOF, the parties have caused this Amended and Restated Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address:

Valo Health, Inc. 399 Boylston St., Suite 505

Boston, MA 02116 Attn: David Berry, CEO

Email: dberry@integraltx.com

399 Boylston St., Suite 505 Boston, MA 02116

Attn: David Berry, CEO

Email: dberry@integraltx.com

c/o Valo Health, Inc.

Address:

Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, as Agent 505 Howard Street, Floor 3 San Francisco, California 94105

Attn: Mr. Peter Sletteland Email: PSletteland@svb.com Valo Health, Inc. (f/k/a Integral Health, Inc.)

David a. Berry, M.D., Ph.D.

Name: David A. Berry, M.D., Ph.D.

Title: President and Chief Executive Officer

Valo Health, LLC (f/k/a Integral Health

Holdings, LLC)

David a. Berry, M.D., Ph.D.

Name: David A. Berry, M.D., Ph.D.

Title: President and Chief Executive Officer

AGENT:

First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to

Silicon Valley Bank))

Peter Stetteland

Name: Peter Sletteland

Title: Vice President

[Signature Page to Amended and Restated Intellectual Property Security Agreement]

EXHIBIT A

Copyrights

Description

Registration/ Application Number Registration/ Application Date

None

ACTIVE\900438463.2

EXHIBIT B

Patents and Trademarks

ACTIVE\900438463.2

The column									
Column		PYRIDÓ [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITÓRS			Country Cla United States of America	asses Ap PC	plication number T/IB2007/054209	Application Date Registration/Grant number 16-Oct-2007 8,518,958	Reg. / Grant date 27-Aug-2013
March Mar									
March Marc									
Manufact Manufact	Valo Health, Inc.	DERIVATIVES OF SQUARIC ACID WITH ANTI-PROLIFERATIVE ACTIVITY	Granted		France			23-Dec-2004 1674457	03-Jun-2009
Member M	Valo Health, Inc.	DERIVATIVES OF SQUARIC ACID WITH ANTI-PROLIFERATIVE ACTIVITY	Granted	Patent	Ireland	040	030696.1	23-Dec-2004 1674457	03-Jun-2009
Martin	Valo Health, Inc.	DERIVATIVES OF SQUARIC ACID WITH ANTI-PROLIFERATIVE ACTIVITY	Granted	Patent	United States of America	11/	/708,793	21-Feb-2007 8,450,348	28-May-2013
Column									
Column C									25-Oct-2022
Column C	Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	Brazil	PC	T/US2011/050321	02-Sep-2011 BR112013004773-9	
Column	Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	Malaysia	PC	T/US2011/050321	02-Sep-2011 MY-190351-A	15-Apr-2022
Second						PC	T/US2011/050321	02-Sep-2011	13-Oct-2017
Secondary Seco									30-Apr-2019
Second State Seco						16/ 16/	/212,360 /538,208		
March Marc	Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	United States of America	17/	/018,196	11-Sep-2020 11,547,701	
March Marc	Valo Health, Inc.	GUANIDINE COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	Mexico	PC	T/US2011/050323	02-Sep-2011 342838	
Control Cont	Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	Mexico	PC	T/US2011/050320	02-Sep-2011 342481	30-Sep-2016
March Marc	Genentech, Inc., Valo Health, Inc.	NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT	Granted	Patent	United States of America	16/	/419,333	22-May-2019 10,647,695	12-May-2020
March Marc									
Common C									
Company Comp	Genentech, Inc., Valo Health, Inc.	PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES	Granted	Patent	United States of America	PĆ	T/CN2013/000214	01-Mar-2013 9,458,172	04-Oct-2016
Column	Genentech, Inc., Valo Health, Inc.	AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES	Pending	Patent	Singapore	102	2017018945	01-Mar-2013	
Section Sect	Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Austria	PĆ	T/CN2013/000216	01-Mar-2013 2820008	14-Dec-2016
Seminary Seminary		AMIDÓ SPIRÓCYCLIC AMIDE AND SULFONÁMIDE DERIVÁTIVES			Belgium				14-Dec-2016
Control of the cont									
Second S									
Control And Mark Am		AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Czech Republic	PC	T/CN2013/000216	01-Mar-2013 2820008	14-Dec-2016
Common C	Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Denmark	PC	T/CN2013/000216	01-Mar-2013 2820008	14-Dec-2016
Second S	Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Spain	PC	T/CN2013/000216	01-Mar-2013 2820008	14-Dec-2016
Semanth Commonwell Common									
Secret 1.5 March 1.5 M									
Second No. Sec	Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES							
Section Comment Comm	Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Ireland	PĆ	T/CN2013/000216	01-Mar-2013 2820008	14-Dec-2016
	Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Italy	PC	T/CN2013/000216	01-Mar-2013 2820008	14-Dec-2016
Seminary Seminary	Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Switzerland	PC	T/CN2013/000216	01-Mar-2013 2820008	14-Dec-2016
Common C									
Common C									
Commit A. C. Security Commit	Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Macedonia (North)	PC	T/CN2013/000216	01-Mar-2013 2820008	14-Dec-2016
Control Cont	Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Netherlands	PC	T/CN2013/000216	01-Mar-2013 2820008	14-Dec-2016
Control A.P. WASCONSTOCK MERCE STATES CONTROL S	Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Poland	PC	T/CN2013/000216	01-Mar-2013 2820008	14-Dec-2016
Security Company Com						PC	T/CN2013/000216	01-Mar-2013 2820008	
Second Content Seco		AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES							
Source Control Contr	Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Singapore	PC	T/CN2013/000216	01-Mar-2013 11201405056U	29-Apr-2016
Part	Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Slovakia	PC	T/CN2013/000216	01-Mar-2013 2820008	14-Dec-2016
Seminary Seminary	Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	Turkey	PC	T/CN2013/000216	01-Mar-2013 2017/03827	14-Dec-2016
	Genentech, Inc., Valo Health, Inc.	AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES	Granted	Patent	United States of America	15/	/936,086	26-Mar-2018 10,730,889	04-Aug-2020
Court Transpection BREATCHE ELECTRON STRUCT GOODS COURT CO		BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY	CPending						01-Nov-2022
Court Propagation		BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY	CPending CPending						
Court Prospected Court Company Court									
Security Propagation County Propagation Propagatio	Courier Therapeutics			Patent	United Kingdom	PC	T/US2020/018680		
Part Count Propriet Part Count Part Part Count Part Part Count Part Part Part Count Part Part	Courier Therapeutics	BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY	CPending	Patent	India	PC	T/US2020/018680	18-Feb-2020	
Counter Prospected Counter		BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY	CPending						
County C									
Count Procession Control Procession Count Procession Control Pro									
Visit Hall, No. BIFCILE [ASS] PRITED MANUE (CELE AS RINGE SHIRTED) Finding Factor Veneralish Courted 11/19/29/88 28-0-2025 13/07/138 23-0-2025 13/07/238	Courier Therapeutics	ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS-I LIKE PROT	TE Pending		United States of America			13-Aug-2020	22 Ion 2019
Month March MCCILLE (A.G.) Principation And Control March	Valo Health, Inc.	BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC6 INHIBITORS	Pending	Patent	Venezuela	000	0057-2016	02-Feb-2016	
March Marc	Valo Health, Inc.	BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC6 INHIBITORS	Granted	Patent	United States of America	16/	/522,082	25-Jul-2019 10,870,645	
SAMETA - ARROS - BETTAL - SAMETA - SAME CANDEL (SEAS) PRINCIPATION (STREET) STREET SAMETA - SAME	Valo Health, Inc.	BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDACG INHIBITORS	Pending	Patent	United States of America	18/	/196,459	12-May-2023	
Valo Hellith, Inc. 3.44KT.4.4AMOG.04 (CTULE [A.5], IPPROCAME COLOS S HOLD, INSTITUTE Father Father Father Carried	Valo Health, Inc.	3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Pending	Patent	Argentina	P 20	0160100295	02-Feb-2016	
SAMEN SAME		3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS							08-Apr-2021
April Harbs, Inc. 3.42Ff AMMOD - RECYCLE (S.A.) PRINCOAMAC ACKOR S A HOLE (INSERTION) Granted Fatter Germany PC/MSZ16(9)05201 C2 + 42-2018 5333747 27-49-2019 April Harbs, Inc. 3.42Ff AMMOD - RECYCLE (S.A.) PRINCOAMAC ACKOR S A HOLE (INSERTION) Granted Fatter France Prince Pri		3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS				PC PC	T/US2016/016201 T/US2016/016201		27-Nov-2019
Value Health, Inc. 3.41KFL-4.4MIRO-SECTULE (A.S.) I PEREDAMIA CADDS AS HOLD INHIBITIONS Granted Fatent Family Facility Family Facility Family Facility Family F	Valo Health, Inc.	3-ALKYL-4-AMIDD-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	China	PC	T/US2016/016201	02-Feb-2016 ZL 201680019311.X	23-Jul-2021
Val Health, Inc. 3ALRYL - AMIDO - BICCULE LEAS, II PYRROZAMAE CADDS AS HOLD A SHIRTONS Granted Fatest Health Inc. 3ALRYL - AMIDO - BICCULE LEAS, II PYRROZAMAE CADDS AS HOLD A SHIRTONS Granted Fatest February	Valo Health, Inc.	3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	Spain	PC	T/US2016/016201	02-Feb-2016 3253747	27-Nov-2019
Valie Health, Inc. 3.44874 - AMIDO-487CCLE [4.5,0] HYBROZAMA EADOR SA HOAD, CHRISTIONS Granted Fatest trail Fatest	Valo Health, Inc.	3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	United Kingdom	PC	T/US2016/016201	02-Feb-2016 3253747	27-Nov-2019
Valie Health, Inc. 3-ALRYL - AMIDO-BETCILE (E.S.) HYDRODAMIA CADDS AS HOLD CHRISTIONS Farther Fatter Haly PCT (INSDE)(10)2010 C2-Feb-2018 \$537347 27-Nov-2019 Valie Health, Inc. 3-ALRYL - AMIDO-BETCILE (E.S.) HYDRODAMIA CADDS AS HOLD CHRISTIONS Fatter Fatter Haly PCT (INSDE)(10)2010 C2-Feb-2018 \$537347 27-Nov-2019 Valie Health, Inc. 3-ALRYL - AMIDO-BETCILE (E.S.) HYDRODAMIA CADDS AS HOLD CHRISTIONS Fatter Fatter Wellow PCT (INSDE)(10)2010 C2-Feb-2018 \$537347 27-Nov-2019 Valie Health, Inc. 3-ALRYL - AMIDO-BETCILE (E.S.) HYDRODAMIA CADDS AS HOLD CHRISTIONS Granted Fatter Health, Inc. 3-ALRYL - AMIDO-BETCILE (E.S.) HYDRODAMIA CADDS AS HOLD CHRISTIONS Fatter Fatter Health, Inc. 3-ALRYL - AMIDO-BETCILE (E.S.) HYDRODAMIA CADDS AS HOLD CHRISTIONS Fatter Fatter Fatter Health, Inc. 3-ALRYL - AMIDO-BETCILE (E.S.) HYDRODAMIA CADDS AS HOLD CHRISTIONS Fatter Fatter		3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS				PC	T/US2016/016201	02-Feb-2016 3253747	27-Nov-2019
Val Health, Inc. 3ALRYL - AMIDO - BICCULE (A.S.) BY PROED AME ACADES AS HOLD A INSERTIONS Facility February Facility Fac									26-Jun-2021
Val Health, Inc. 3-ALKYL - AMIDO-EMCLICE (A.S.) HYDROCAMAE CADDS AS HOLD NINISTICES Facility Facility									
Valis Health, Inc. 3-ARXY-A-AMIDO-BIFCCICE (A.S.) HYDROCAMAC ACIDS AS HOLD (INHERTORS Farlet February February	Valo Health, Inc.	3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Pending	Patent	Korea (South)	PC	T/US2016/016201	02-Feb-2016	
Valis Health, Inc. 3-ALRYL - AMIDO-SECTICE LES, SE THERODAMIA CADID-S & Float CHRISTIONS Factor Facto	Valo Health, Inc.	3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	Mexico	PC	T/US2016/016201	02-Feb-2016 373137	20-Apr-2020
Value Healthy, Inc. 3-ALRYL-A-MANIDOBIFCCLIE (A.S.) HYDROCAMAL CADIDS & SHOLD ANIBITOTISS Granted February Suppose Februa	Valo Health, Inc.	3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Pending	Patent	New Zealand	PC	T/US2016/016201	02-Feb-2016	
Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Granted Fattent Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Granted Fattent Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Granted Fattent Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Fattent Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Fattent Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Fattent Fattent Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Fattent Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Granted Fattent Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Granted Fattent Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Granted Fattent Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Granted Fattent Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Granted Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Granted Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Granted Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Granted Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Granted Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Granted Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS Granted Value Health, Inc. 3-ALRYL - ANNIDOBICCULE [A.S.) HYROED/AME CADDS AS HOLD A-INSTETIONS	Valo Health, Inc.	3-ALKYL-4-AMIDD-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	Sweden	PC	T/US2016/016201	02-Feb-2016 3253747	27-Nov-2019
Val Health, Inc. 3-ALKYL-4-MINDO-BETCLICE (A.S.) HYDROCAMAE CADDS AS HOLD CHRISTIONS Farlet Fa			Granted						
Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Factor Factor Factor Factor Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Factor Factor Factor Factor Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Factor Factor Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Factor Factor Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Granted Factor Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Granted Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Granted Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Granted Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Granted Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Granted Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Granted Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Granted Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Granted Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Granted Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Granted Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Granted Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Granted Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Granted Valo Health, Inc. 3-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (ACIDS AS HOLD NIBETORS Granted Valo Health, Inc. 4-ALKYL-4-MINDO-GET/CLIC [4,5,0] HYRODO/AME (AC	Valo Health, Inc.	3-ALKYL-4-AMIDÓ-BICYCLIC [4,5,0] HYDRÓXAMIC ACIDS AS HDAC INHIBITÓRS	Pending	Patent	Venezuela	000	0054-2016	02-Feb-2016	
Valo Health, Inc. 3-ALKYL-4-MIRDO-GET/CLE [4,5,0] HYRODO-MARIC ACIDS AS HOLD CHRISTIONS Feeling Feltent Talkgrown 100212000558 02-Feb-2015 (F8557) 22-Inc. 2002 Valo Health, Inc. 3-ALKYL-4-MIRDO-GET/CLE [4,5,0] HYRODO-MARIC ACIDS AS HOLD CHRISTIONS Granted Feltent United States of America 15/013,814 02-Feb-2015 (F8557) 22-Inc. 2002 Valo Health, Inc. 3-ALKYL-4-MIRDO-GET/CLE [4,5,0] HYRODO-MARIC ACIDS AS HOLD CHRISTIONS Granted Feltent United States of America 16/219,303 13-Dec 2018 10,465,900 05-Feb-2019 Valo Health, Inc. 3-ALKYL-4-MIRDO-GET/CLE [4,5,0] HYRODO-MARIC ACIDS AS HOLD CHRISTIONS Granted Feltent United States of America 16/219,303 13-Dec 2018 10,465,900 22-Dec 2019 Valo Health, Inc. 3-ALKYL-4-MIRDO-GET/CLE [4,5,0] HYRODO-MARIC ACIDS AS HOLD CHRISTIONS Granted Feltent United States of America 16/219,305 13-Dec 2018 10,465,900 05-Feb-2019 Valo Health, Inc. 3-ALKYL-4-MIRDO-GET/CLE [4,5,0] HYRODO-MARIC ACIDS AS HOLD CHRISTIONS Granted Feltent United States of America 16/219,600 13-Dec 2018 10,465,900 05-Feb-2019 Valo Health, Inc. 3-ALKYL-4-MIRDO-GET/CLE [4,5,0] HYRODO-MARIC ACIDS AS HOLD CHRISTIONS Granted Feltent United States of America 16/219,600 13-Dec 2018 10,465,900 05-Feb-2019 Valo Health, Inc. 3-ALKYL-4-MIRDO-GET/CLE [4,5,0] HYRODO-MARIC ACIDS AS HOLD CHRISTIONS Granted United States of America 16/59,67,000 13-Dec 2019 10,465,910 05-Feb-2019 1	Valo Health, Inc.	3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	Mexico	MX	X/a/2020/003488	02-Feb-2016 392538	
Valo Health, Inc. 34AKYL-4-AMIDO-GENCLIC (4,5,0) HYRODO/AMAC CADDS AS HOAC INHIBITIONS Granted Fates Patent United States of America 15/23/38.13 30-02-2013 13,646,090 55 +02-2019 Valo Health, Inc. 34AKYL-4-AMIDO-GENCIUC (4,5,0) HYRODO/AMAC CADDS AS HOAC INHIBITIONS Granted Patent United States of America 16/219,381 13-0e-2013 13,646,090 55 +02-2019 Valo Health, Inc. 34AKYL-4-AMIDO-GENCIUC (4,5,0) HYRODO/AMAC CADDS AS HOAC INHIBITIONS Granted Patent United States of America 16/219,382 13-0e-2013 10,446,762 29-02.2019 Valo Health, Inc. 34AKYL-4-AMIDO-GENCIUC (4,5,0) HYRODO/AMAC CADDS AS HOAC INHIBITIONS Granted Patent United States of America 16/219,688 13-0e-2013 10,462,000 55-0e-2019 Valo Health, Inc. 34AKYL-4-AMIDO-GENCIUC (4,5,0) HYRODO/AMAC CADDS AS HOAC INHIBITIONS Granted Patent United States of America 16/219,689 13-0e-2013 10,462,000 55-0e-2019 Valo Health, Inc. 34AKYL-4-AMIDO-GENCIUC (4,5,0) HYRODO/AMAC CADDS AS HOAC INHIBITIONS Granted Patent United States of America 16/219,889 13-0e-2013 10,462,000 55-	Valo Health, Inc.	3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Pending	Patent	Singapore	102	202100915R	02-Feb-2016	
Valo Health, Inc. 34AKT-4-AMIDO-BICCIDE (4.5.0) HYDRODAMIC ACIDE AS HOAC INHEITORS Granted Patent United States of America 15/21/9.582 13-Dec 2013 10,452,76 15-Oct. 2019 Valo Health, Inc. 34AKT-4-AMIDO-BICCIDE (4.5.0) HYDRODAMIC ACIDS AS HOAC INHEITORS Granted Patent United States of America 16/219,688 13-Dec 2013 10,463,910 05-Nov-2019 Valo Health, Inc. 34AKT-4-AMIDO-BICCIDE (4.5.0) HYDRODAMIC ACIDS AS HOAC INHEITORS Granted Patent United States of America 16/219,689 13-Dec 2013 10,463,910 05-Nov-2019 Valo Health, Inc. 34AKT-4-AMIDO-BICCIDE (4.5.0) HYDRODAMIC ACIDS AS HOAC INHEITORS Granted Patent United States of America 16/219,689 13-Dec 2013 10,463,910 05-Nov-2019 Valo Health, Inc. 34AKT-4-AMIDO-BICCIDE (4.5.0) HYDRODAMIC ACIDS AS HOAC INHEITORS Granted Patent United States of America 16/557,007 13-Dec 2013 10,463,910 27-Apr-2021 Valo Health, Inc. 34AKT-4-AMIDO-BICCIDE (4.5.0) HYDRODAMIC ACIDS AS HOAC INHEITORS Ferbild United States of America 17/53,321 23-Apr-2021 Valo Health, Inc. 34AKT-4-AMIDO-BICCIDE (4.5.0) HYDRODAMIC ACIDS AS HOAC INHEITORS Ferbild U	Valo Health, Inc.	3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	United States of America	15/	/013,814	02-Feb-2016 10,214,500	26-Feb-2019
Valo Health, Inc. 34ARYL-4-AMIDO-BICCIAC [4,5,0] HYRODOXAMIC ACIDS AS HOAD, NINETTONS Granted Fattent Unded States of America 15/219,688 13-0e-2018 10,457,652 29-0d-2019 Valo Health, Inc. 34ARYL-4-AMIDO-BICCIAC [4,5,0] HYRODOXAMIC ACIDS AS HOAD, NINETTONS Granted Fattent Unded States of America 15/219,689 13-0e-2018 10,463,910 55-90-2019 Valo Health, Inc. 34ARYL-4-AMIDO-BICCIAC [4,5,0] HYRODOXAMIC ACIDS AS HOAD, NINETTONS Granted Fattent Unded States of America 15/957,000 13-9e-2019 10,988,450 27-Apr-2021 Valo Health, Inc. 34ARYL-4-AMIDO-BICCIAC [4,5,0] HYRODOXAMIC ACIDS AS HOAD, NINETTONS Fending Fattent Unded States of America 17/98,821 23-Apr-2021 Valo Health, Inc. 34ARYL-4-AMIDO-BICCIAC [4,5,0] HYRODOXAMIC ACIDS AS HOAD, NINETTONS Fending Fattent Unded States of America 17/98,821 23-Apr-2021 Valo Health, Inc. 34ARYL-4-AMIDO-BICCIAC [4,5,0] HYRODOXAMIC ACIDS AS HOAD, NINETTONS Fending Fattent Unded States of America 17/98,821 23-Apr-2021 Valo Health, Inc. 34ARYL-4-AMIDO-BICCIAC [4,5,0] HYRODOXAMIC ACIDS AS HOAD, NINETTONS Fending Fattent Unded States of Ame	Valo Health, Inc.	3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS		Patent	United States of America	16/	/219,592	13-Dec-2018 10,442,776	15-Oct-2019
Valor Healthy, Inc. 3444XY-4-AMIDO-GHICCIAC [4,5,0] HY00DCAMAMIC ACIDS AS HOLD, INHIBITORS Granted Patent Unded States of America 16/21/21/29/85 13-Dec 2018 [10,421/72 24-Sep-2019 [10,	Valo Health, Inc.	3-ALKYL-4-AMIDD-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	United States of America	16/	/219,648	13-Dec-2018 10,457,652	29-Oct-2019
Valo Health, Inc. 3-MARYL-4-MINDO-BLYCKEZ [4,5,0] HYDROXAMIC ACIDS AS HOLD, CHNIETTORS Feeding Fatent Unded States of America 17/28,321 23-Apr-2021 Valo Health, Inc. PERIOD AND PHIZOLO OF MINIONE/AS MERIURINFO TRANSITION FROM THE PROPERTY OF A STATE AND ADMINISTRATION FROM THE PROPERTY OF A STATE ADMINISTRATION FRO	Valo Health, Inc.	3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	United States of America	16/	/219,685	13-Dec-2018 10,421,732	24-Sep-2019
	Valo Health, Inc.	3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Pending	Patent	United States of America	17/	/238,321	23-Apr-2021	who ener
									06-Nov-2019

Owners Valo Health, Inc.	Record name PYRROLÓ AND PYRAZÓLÓPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI	Status DIGranted	Module Patent	Country Classes Australia	Application number PCT/US2015/067831	Application Date Registration/Grant number 29-Dec-2015 2015374170	Reg. / Grant date 25-Mar-2021
Valo Health, Inc. Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITE PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITE		Patent Patent	Brazil Canada	PCT/US2015/067831 PCT/US2015/067831	29-Dec-2015 29-Dec-2015	
Valo Health, Inc. Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI		Patent Patent	Switzerland China	PCT/US2015/067831 PCT/US2015/067831	29-Dec-2015 3240791 29-Dec-2015 ZL201580077002.3	06-Nov-2019 17-Dec-2019
Valo Health, Inc. Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI		Patent Patent	Germany Spain	PCT/US2015/067831 PCT/US2015/067831	29-Dec-2015 3240791 29-Dec-2015 3240791	06-Nov-2019 06-Nov-2019
Valo Health, Inc. Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI	OlGranted	Patent Patent	France United Kingdom	PCT/US2015/067831 PCT/US2015/067831	29-Dec-2015 3240791 29-Dec-2015 3240791	06-Nov-2019 06-Nov-2019
Valo Health, Inc. Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI	OlGranted	Patent Patent	Hong Kong Ireland	18105707.3 PCT/US2015/067831	29-Dec-2015 1246284 29-Dec-2015 3240791	04-Jun-2021 06-Nov-2019
Valo Health, Inc. Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITIT PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITIT	OlGranted	Patent Patent	India	PCT/US2015/067831 PCT/US2015/067831	29-Dec-2015 354622 29-Dec-2015 3240791	29-Dec-2020 06-Nov-2019
Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI	OlGranted	Patent	Italy Japan	PCT/US2015/067831	29-Dec-2015 6649388	20-Jan-2020
Valo Health, Inc. Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITY PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITY	OlGranted	Patent Patent	Korea (South) Switzerland	PCT/US2015/067831 PCT/US2015/067831	29-Dec-2015 29-Dec-2015 3240791	06-Nov-2019
Valo Health, Inc. Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITE PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITE	OlGranted	Patent Patent	Macao Mexico	J/004073 PCT/US2015/067831	29-Dec-2015 J/004073 29-Dec-2015 373788	17-Jun-2020 23-Mar-2020
Valo Health, Inc. Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITE PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITE	OIPending	Patent Patent	Netherlands New Zealand	PCT/US2015/067831 PCT/US2015/067831	29-Dec-2015 3240791 29-Dec-2015	06-Nav-2019
Valo Health, Inc. Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBIT PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI	OlGranted	Patent Patent	Pakistan Singapore	860/2015 PCT/US2015/067831	30-Dec-2015 29-Dec-2015 11201704897Q	29-Dec-2021
Valo Health, Inc. Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBIT PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI	DIGranted	Patent Patent	Taiwan United States of America	104144096 14/982,127	28-Dec-2015 I698436 29-Dec-2015 9,902,728	11-Jul-2020 27-Feb-2018
Valo Health, Inc. Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI		Patent Patent	Venezuela South Africa	2015-001055 PCT/US2015/067831	29-Dec-2015 29-Dec-2015	
Valo Health, Inc. Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI	OIPending	Patent Patent	European Patent Office (EPO) Hong Kong	19207235.3 42020016503.3	29-Dec-2015 29-Dec-2015	
Valo Health, Inc. Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI	OIPending	Patent Patent	New Zealand Talwan	771514 109118957	29-Dec-2015 28-Dec-2015 1770525	11-Jul-2022
Valo Health, Inc. Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI	OlGranted	Patent Patent	United States of America United States of America	15/874,163 16/517,149	18-Jan-2018 10,377,760 19-Jul-2019 10,934,299	13-Aug-2019 02-Mar-2021
Valo Health, Inc.	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITI	OIPending	Patent	United States of America	17/186,915	26-Feb-2021	
Valo Health, Inc. Valo Health, Inc.	PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEAS PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEAS		Patent Patent	United States of America United States of America	14/982,131 15/988,790	29-Dec-2015 10,000,495 24-May-2018 10,351,571	19-Jun-2018 16-Jul-2019
Valo Health, Inc. Valo Health, Inc.	PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEAS PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEAS		Patent Patent	United States of America United States of America	16/449,599 17/230,603	24-Jun-2019 10,981,915 14-Apr-2021	20-Apr-2021
Valo Health, Inc. Valo Health, Inc.	THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted Granted	Patent Patent	United States of America United States of America	15/015,563 15/909,200	04-Feb-2016 9,932,351 01-Mar-2018 10,377,767	03-Apr-2018 13-Aug-2019
Valo Health, Inc. Valo Health, Inc.	THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Granted Pending	Patent Patent	United States of America United States of America	16/515,194 17/161,324	18-Jul-2019 10,906,916 28-Jan-2021	02-Feb-2021
Valo Health, Inc.	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDIN SOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDIN	NCGranted	Patent	United States of America United States of America	15/015,566 15/907,007	04-Feb-2016 9,938,300	10-Apr-2018 13-Aug-2019
Valo Health, Inc. Valo Health, Inc.	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDIN	NCGranted	Patent Patent	United States of America	16/515,281	27-Feb-2018 10,377,773 18-Jul-2019 10,927,130	23-Feb-2021
Valo Health, Inc. Valo Health, Inc.	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDIN QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 I	N Granted	Patent Patent	United States of America United States of America	17/179,046 15/015,571	18-Feb-2021 04-Feb-2016 9,840,491	12-Dec-2017
Valo Health, Inc. Valo Health, Inc.	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 I QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 I		Patent Patent	United States of America United States of America	15/837,393 16/179,061	11-Dec-2017 10,513,507 02-Nov-2018 10,513,508	24-Dec-2019 24-Dec-2019
Valo Health, Inc. Valo Health, Inc.	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 I QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 I		Patent Patent	United States of America United States of America	16/179,071 16/179,099	02-Nov-2018 10,519,127 02-Nov-2018 10,508,098	31-Dec-2019 17-Dec-2019
Valo Health, Inc. Valo Health, Inc.	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN -SPECIFIC PROTEASE 7 I QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN -SPECIFIC PROTEASE 7 I	N Granted	Patent Patent	United States of America United States of America	16/179,111 16/179,117	02-Nov-2018 10,519,128 02-Nov-2018 10,519,129	31-Dec-2019 31-Dec-2019
Valo Health, Inc. Valo Health, Inc.	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 I	N Granted	Patent	United States of America	16/179,125 16/694,500	02-Nov-2018 10,519,130	31-Dec-2019
Valo Health, Inc.	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 I QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 I	N Pending	Patent Patent	United States of America United States of America	17/096,349	25-Nov-2019 10,836,741 12-Nov-2020	17-Nov-2020
Valo Health, Inc. Valo Health, Inc.	[6,6] FUSED BICYCLIC HDACS INHIBITORS [6,6] FUSED BICYCLIC HDACS INHIBITORS	Pending Granted	Patent Patent	Pakistan United States of America	537/2016 15/255,817	02-Sep-2016 02-Sep-2016 10,029,995	24-Jul-2018
Valo Health, Inc. Valo Health, Inc.	[6,6] FUSED BICYCLIC HDACS INHIBITORS [6,6] FUSED BICYCLIC HDACS INHIBITORS	Pending Granted	Patent Patent	Venezuela United States of America	2016-000479 16/003,861	02-Sep-2016 08-Jun-2018 10,370,343	06-Aug-2019
Valo Health, Inc. Valo Health, Inc.	[6,6] FUSED BICYCLIC HDACS INHIBITORS [6,6] FUSED BICYCLIC HDACS INHIBITORS	Granted Granted	Patent Patent	United States of America United States of America	16/449,675 17/066,385	24-Jun-2019 10,829,460 08-Oct-2020 11,414,392	10-Nov-2020 16-Aug-2022
Valo Health, Inc. Valo Health, Inc.	[6,6] FUSED BICYCLIC HDACS INHIBITORS 3-SPIRO-7-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS	Pending Granted	Patent Patent	United States of America United States of America	18/096,712 15/130,613	13-Jan-2023 15-Apr-2016 9,630,922	25-Apr-2017
Valo Health, Inc. Valo Health, Inc.	THENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS THENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending Granted	Patent Patent	Canada China	PCT/US2017/017690 PCT/US2017/017690	13-Feb-2017 13-Feb-2017 ZL201780021667.1	14-Jan-2022
Valo Health, Inc.	THENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	Belgium	PCT/US2017/017690	13-Feb-2017 3414252	06-Jul-2022 06-Jul-2022
Valo Health, Inc. Valo Health, Inc.	THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted Granted	Patent Patent	Switzerland Germany	PCT/US2017/017690 PCT/US2017/017690	13-Feb-2017 3414252 13-Feb-2017 602017059202.1	06-Jul-2022
Valo Health, Inc. Valo Health, Inc.	THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted Granted	Patent Patent	France United Kingdom	PCT/US2017/017690 PCT/US2017/017690	13-Feb-2017 3414252 13-Feb-2017 3414252	06-Jul-2022 06-Jul-2022
Valo Health, Inc. Valo Health, Inc.	THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted Granted	Patent Patent	Ireland Switzerland	PCT/US2017/017690 PCT/US2017/017690	13-Feb-2017 3414252 13-Feb-2017 3414252	06-Jul-2022 06-Jul-2022
Valo Health, Inc. Valo Health, Inc.	THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	United States of America Taiwan	PCT/US2017/017690 105103340	13-Feb-2017 10,913,753 02-Feb-2016 (697486	09-Feb-2021 01-Jul-2020
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC (4,5,0) HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC (4,5,0) HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	United States of America Australia	15/013,816 PCT/US2016/016200	02-Feb-2016 10,239,845 02-Feb-2016 2016215431	26-Mar-2019 25-Mar-2021
Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Pending	Patent	Brazil	PCT/US2016/016200	02-Feb-2016	23 Wai - 2021
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Pending Granted	Patent Patent	Canada China	PCT/US2016/016200 PCT/US2016/016200	02-Feb-2016 02-Feb-2016 ZL201680020984.7	22-Oct-2021
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	Austria Belgium	16704357.9 16704357.9	02-Feb-2016 E1439858 02-Feb-2016 3292116	20-Oct-2021 20-Oct-2021
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	Switzerland Germany	16704357.9 16704357.9	02-Feb-2016 3292116 02-Feb-2016 602016065078.9	20-Oct-2021 20-Oct-2021
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	Denmark Spain	16704357.9 16704357.9	02-Feb-2016 3292116 02-Feb-2016 3292116	20-Oct-2021 20-Oct-2021
Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	Finland France	16704357.9 16704357.9	02-Feb-2016 3292116 02-Feb-2016 3292116	20-Oct-2021 20-Oct-2021
Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	United Kingdom	16704357.9	02-Feb-2016 3292116	20-Oct-2021
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	Greece Hungary	16704357.9 16704357.9	02-Feb-2016 3292116 02-Feb-2016 3292116	20-Oct-2021 20-Oct-2021
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	ireland Italy	16704357.9 16704357.9	02-Feb-2016 3292116 02-Feb-2016 502022000001790	20-Oat-2021 20-Oat-2021
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	Switzerland Luxembourg	16704357.9 16704357.9	02-Feb-2016 3292116 02-Feb-2016 3292116	20-Oct-2021 20-Oct-2021
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDÓ-BICYCLIC [4,5,0] HYDRÓXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDÓ-BICYCLIC [4,5,0] HYDRÓXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	Netherlands Norway	16704357.9 16704357.9	02-Feb-2016 3292116 02-Feb-2016 3292116	20-Oct-2021 20-Oct-2021
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	Poland Portugal	16704357.9 16704357.9	02-Feb-2016 3292116 02-Feb-2016 3292116	20-Oct-2021 20-Oct-2021
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	Sweden Turkey	16704357.9 16704357.9	02-Feb-2016 3292116 02-Feb-2016 2021/020450	20-Oct-2021 20-Oct-2021
Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent	Hong Kong	18110821.4 PCT/US2016/016200	02-Feb-2016 1251550 02-Feb-2016 255111	30-Jun-2022
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Pending	Patent Patent	Israel New Zealand	PCT/US2016/016200	02-Feb-2016	01-May-2021
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Pending	Patent Patent	Singapore Thailand	PCT/US2016/016200 PCT/US2016/016200	02-Feb-2016 11201708622U 02-Feb-2016	19-Feb-2021
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	Taiwan United States of America	109117117 16/173,871	02-Feb-2016 1776156 29-Oct-2018 10,377,726	01-Sep-2022 13-Aug-2019
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Pending Pending	Patent Patent	China European Patent Office (EPO)	202111210558.9 21203535.6	02-Feb-2016 02-Feb-2016	
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Pending	Patent Patent	Israel New Zealand	279830 772484	02-Feb-2016 279830 02-Feb-2016	03-Nov-2022
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC (4,5,0) HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC (4,5,0) HYDROXAMIC ACIDS AS HDAC INHIBITORS	Pending Granted	Patent Patent	Singapore United States of America	10202100916P 16/220.035	02-Feb-2016 14-Dec-2018 10,479,772	19-Nov-2019
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	United States of America United States of America	16/220,041 16/220,046	14-Dec-2018 10,450,284 14-Dec-2018 10,472,337	22-Oct-2019 12-Nov-2019
Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	United States of America	16/220,049	14-Dec-2018 10,472,357 14-Dec-2018 10,494,353 16-Oct-2019 10,829,461	03-Dec-2019
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	United States of America United States of America	16/654,704 17/031,812	24-Sep-2020 11,274,084	10-Nov-2020 15-Mar-2022
Valo Health, Inc. Valo Health, Inc.	3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Pending Granted	Patent Patent	United States of America United States of America	17/691,186 15/013,820	10-Mar-2022 02-Feb-2016 10,214,501	26-Feb-2019
Valo Health, Inc. Valo Health, Inc.	3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	United States of America United States of America	16/218,108 16/218,114	12-Dec-2018 10,414,738 12-Dec-2018 10,428,031	17-Sep-2019 01-Oct-2019
Valo Health, Inc. Valo Health, Inc.	3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	United States of America United States of America	16/218,122 16/662,131	12-Dec-2018 10,513,501 24-Oct-2019 10,829,462	24-Dec-2019 10-Nov-2020
Valo Health, Inc. Valo Health, Inc.	3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	United States of America United States of America	16/218,126 16/218,132	12-Dec-2018 10,421,731 12-Dec-2018 10,450,283	24-Sep-2019 22-Oct-2019
Valo Health, Inc.	3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted	Patent	United States of America	17/031,814 15/013.826	24-Sep-2020 11,279,681 02-Feb-2016 10.112,915	22-Mar-2022
Valo Health, Inc. Valo Health, Inc.	3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	United States of America United States of America	16/133,918	18-Sep-2018 10,494,351	30-Oct-2018 03-Dec-2019
Valo Health, Inc. Valo Health, Inc.	3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	United States of America United States of America	16/133,922 16/222,868	18-Sep-2018 10,494,352 17-Dec-2018 10,494,354	03-Dec-2019 03-Dec-2019
Valo Health, Inc. Valo Health, Inc.	3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS 3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS	Granted Granted	Patent Patent	United States of America United States of America	16/660,015 16/222,871	22-Oct-2019 10,822,316 17-Dec-2018 10,501,424	03-Nov-2020 10-Dec-2019
Valo Health, Inc. Valo Health, Inc.	3-ARYL-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted Granted	Patent Patent	United States of America Austria	17/031,815 PCT/US2017/017691	24-Sep-2020 11,274,085 13-Feb-2017 1191152	15-Mar-2022 16-Oct-2019
Valo Health, Inc. Valo Health, Inc.	THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending Granted	Patent Patent	Canada Switzerland	PCT/US2017/017691 PCT/US2017/017691	13-Feb-2017 13-Feb-2017 3414251	16-Oct-2019
Valo Health, Inc. Valo Health, Inc. Valo Health, Inc.	THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted Granted	Patent Patent	Switzeriand Cermany	PCT/US2017/017691 PCT/US2017/017691 PCT/US2017/017691	13-Feb-2017 3414251 13-Feb-2017 ZL201780021734.X 13-Feb-2017 3414251	14-Jan-2022 16-Oct-2019
Valo Health, Inc.	THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	Spain	PCT/US2017/017691	13-Feb-2017 3414251	16-Oct-2019
Valo Health, Inc. Valo Health, Inc.	THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted Granted	Patent Patent	France United Kingdom	PCT/US2017/017691 PCT/US2017/017691	13-Feb-2017 3414251 13-Feb-2017 3414251	16-Oct-2019 16-Oct-2019
Valo Health, Inc. Valo Health, Inc.	THIENOPYRIDINE CARBÓXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS THIENOPYRIDINE CARBÓXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted Granted	Patent Patent	Ireland Italy	PCT/US2017/017691 PCT/US2017/017691	13-Feb-2017 3414251 13-Feb-2017 3414251	16-Oct-2019 16-Oct-2019
Valo Health, Inc.	THIENOPYRIDINE CARBÓXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	Switzerland	PCT/US2017/017691	13-Mar-2017 3414251	16-Oct-2019

Owners	Record name	Status	Module	Country Classes	Application number	Application Date Registration/Grant number	Reg. / Grant date
Valo Health, Inc.	THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted	Patent	Netherlands	PCT/US2017/017691	13-Feb-2017 3414251	16-Oct-2019
Valo Health, Inc. Valo Health, Inc.	THIENOPYRIDINE CARBOXÁMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS THIENOPYRIDINE CARBOXÁMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted Granted	Patent Patent	United States of America United States of America	PCT/US2017/017691 17/003,356	13-Feb-2017 10,889,592 26-Aug-2020 11,325,917	12-Jan-2021 10-May-2022
Valo Health, Inc.	3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS	Granted	Patent	United States of America	15/130,603	15-Apr-2016 9,637,453	02-May-2017
Valo Health, Inc. Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDACS INHIBITORS ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDACS INHIBITORS	Pending Pending	Patent Patent	Canada Costa Rica	PCT/US2016/022029 PCT/US2016/022029	11-Mar-2016 11-Mar-2016	
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDACS INHIBITORS	Pending	Patent	Korea (South)	PCT/US2016/022029	11-Mar-2016	
Valo Health, Inc. Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDACS INHIBITORS ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDACS INHIBITORS	Pending Granted	Patent Patent	New Zealand United States of America	PCT/US2016/022029 15/067.605	11-Mar-2016 11-Mar-2016 9.745,253	29-Aug-2017
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDACS INHIBITORS	Pending	Patent	European Patent Office (EPO)	21169630.7	11-Mar-2016	· ·
Valo Health, Inc. Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HIDACS INHIBITORS ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HIDACS INHIBITORS	Pending Pending	Patent Patent	Hong Kong New Zealand	42022056162.5 773721	11-Mar-2016 11-Mar-2016	
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDACS INHIBITORS	Granted	Patent	United States of America	15/925,559	19-Mar-2018 10,266,487	23-Apr-2019
Valo Health, Inc. Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDACS INHIBITORS ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDACS INHIBITORS	Granted Granted	Patent Patent	United States of America United States of America	16/387,937 16/689,252	18-Apr-2019 10,508,077 20-Nov-2019 10,988,441	17-Dec-2019 27-Apr-2021
Valo Health, Inc.	ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDACS INHIBITORS	Pending	Patent	United States of America	17/238,529	23-Apr-2021	
Valo Health, Inc. H. Lee Moffitt Cancer Center and Research In	METHODS USING HDAC11 INHIBITORS H) METHODS USING HDAC11 INHIBITORS	Granted Granted	Patent Patent	United States of America United States of America	16/202,207 16/202,210	28-Nov-2018 10,508,088 28-Nov-2018 10,538,496	17-Dec-2019 21-Jan-2020
Valo Health, Inc.	METHODS USING HDAC11 INHIBITORS	Granted	Patent	United States of America	16/688,469	19-Nov-2019 11,345,672	31-May-2022
Valo Health, Inc. Valo Health, Inc.	METHODS USING HDAC11 INHIBITORS 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Pending Granted	Patent Patent	United States of America Belgium	17/712,001 PCT/US2017/037970	01-Apr-2022 16-Jun-2017 3472131	19-Feb-2020
Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted	Patent	Switzerland	PCT/US2017/037970	16-Jun-2017 3472131	19-Feb-2020
Valo Health, Inc. Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted Granted	Patent Patent	Germany France	PCT/US2017/037970 PCT/US2017/037970	16-Jun-2017 3472131 16-Jun-2017 3472131	19-Feb-2020 19-Feb-2020
Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted	Patent	United Kingdom	PCT/US2017/037970	16-Jun-2017 3472131	19-Feb-2020
Valo Health, Inc. Valo Health, Inc.	2-SPIRO-S- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS 2-SPIRO-S- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted Granted	Patent Patent	Ireland Switzerland	PCT/US2017/037970 PCT/US2017/037970	16-Jun-2017 3472131 16-Jun-2017 3472131	19-Feb-2020 19-Feb-2020
Valo Health, Inc.	2-SPIRÓ-S- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted	Patent	Netherlands	PCT/US2017/037970	16-Jun-2017 3472131	19-Feb-2020
Valo Health, Inc. Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Granted Granted	Patent Patent	United States of America United States of America	PCT/US2017/037970 16/719,332	16-Jun-2017 10,555,935 18-Dec-2019 10,874,649	11-Feb-2020 29-Dec-2020
Valo Health, Inc.	2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS	Pending	Patent	United States of America	17/130,704	22-Dec-2020	25 000 2020
Valo Health, Inc. Valo Health, Inc.	ISOINDOLINES AS HDAC INHIBITORS ISOINDOLINES AS HDAC INHIBITORS	Pending Pending	Patent Patent	Australia Canada	PCT/US2019/028026 PCT/US2019/028026	18-Apr-2019 18-Apr-2019	
Valo Health, Inc.	ISOINDOLINES AS HDAC INHIBITORS	Pending	Patent	China	PCT/US2019/028026	18-Apr-2019	
Valo Health, Inc. Valo Health, Inc.	ISOINDOLINES AS HDAC INHIBITORS ISOINDOLINES AS HDAC INHIBITORS	Pending Pending	Patent Patent	European Patent Office (EPO) Israel	PCT/US2019/028026 PCT/US2019/028026	18-Apr-2019 18-Apr-2019	
Valo Health, Inc.	ISOINDOLINES AS HDAC INHIBITORS	Pending	Patent	Japan	PCT/US2019/028026	18-Apr-2019	
Valo Health, Inc. Valo Health, Inc.	ISOINDOLINES AS HDAC INHIBITORS ISOINDOLINES AS HDAC INHIBITORS	Granted Pending	Patent Patent	Mexico New Zealand	P CT/US2019/028026 P CT/US2019/028026	18-Apr-2019 Awaiting 18-Apr-2019	24-Apr-2023
Valo Health, Inc.	SOINDOLINES AS HOAC INVIBITORS	Granted	Patent	United States of America	P CT/US2019/028026	18-Apr-2019 11,535,607	27-Dec-2022
Valo Health, Inc. Valo Health, Inc.	ISOINDOLINES AS HOAC INHIBITORS ISOINDOLINES AS HOAC INHIBITORS	Pending	Patent Patent	South Africa United States of America	PCT/US2019/028026 17/984.065	18-Apr-2019 09-Nov-2022	
Valo Health, Inc.	SOINDOLINES AS HOAC INVIBITORS	Pending Pending	Patent	Hong Kong	62021036421.7	18-Apr-2019	
Valo Health, Inc. Valo Health, Inc.	INHIBITING DEUBIQUITINASE USP25 AND USP28 INHIBITING DEUBIQUITINASE USP25 AND USP28	Pending	Patent	China European Patent Office (EPD)	PCT/US2019/045734 PCT/US2019/045734	08-Aug-2019	
Valo Health, Inc.	INHIBITING DEUBIQUITINASE USP25 AND USP28	Pending Pending	Patent Patent	Hong Kong	62021042894.7	08-Aug-2019 23-Nov-2021	
Valo Health, Inc.	INHIBITING DEUBIQUITINASE USP25 AND USP28 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	United States of America	PCT/US2019/045734 PCT/US2018/046061	08-Aug-2019	
Valo Health, Inc. Valo Health, Inc.	CARBOXAMIDES AS OBIQUITIN-SPECIFIC PROTEASE INHIBITORS CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Granted Pending	Patent Patent	Australia Canada	PCT/US2018/046061	09-Aug-2018 2018316254 09-Aug-2018	27-Oct-2022
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS CARROXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	European Patent Office (EPO)	PCT/US2018/046061	09-Aug-2018	
Valo Health, Inc. Valo Health, Inc.	CARBOXAMIDES AS OBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending Granted	Patent Patent	Hong Kong United States of America	62020020254.2 PCT/US2018/046061	09-Aug-2018 09-Aug-2018 11,524,966	13-Dec-2022
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	Australia	PCT/US2019/045732	08-Aug-2019	
Valo Health, Inc. Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending Pending	Patent Patent	Canada China	PCT/US2019/045732 PCT/US2019/045732	08-Aug-2019 08-Aug-2019	
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	European Patent Office (EPO)	PCT/US2019/045732	08-Aug-2019	
Valo Health, Inc. Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending Pending	Patent Patent	Hong Kong Israel	62021042893.9 PCT/US2019/045732	23-Nov-2021 08-Aug-2019	
Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending	Patent	Mexico	PCT/US2019/045732	08-Aug-2019	
Valo Health, Inc. Valo Health, Inc.	CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS	Pending Pending	Patent Patent	New Zealand United States of America	PCT/US2019/045732 PCT/US2019/045732	08-Aug-2019 08-Aug-2019	
Valo Health, Inc.	INHIBITING USP36	Pending	Patent	China	PCT/US2020/030833	30-Apr-2020	
Valo Health, Inc., Valo Health, LLC Valo Health, Inc., Valo Health, LLC	INHIBITING USP36 INHIBITING USP36	Pending Pending	Patent Patent	European Patent Office (EPO) Japan	PCT/US2020/030833 PCT/US2020/030833	30-Apr-2020 30-Apr-2020	
Valo Health, Inc., Valo Health, LLC	INHIBITING USP36	Pending	Patent	United States of America	PCT/US2020/030833	30-Apr-2020	
Valo Health, Inc., Valo Health, LLC Valo Health, Inc., Valo Health, LLC	INHIBITING USP36 INHIBITING TRABID	Pending Pending	Patent Patent	Hong Kong United States of America	62022059873.9 PCT/US2020/031214	08-Sep-2022 02-May-2020	
Valo Health, Inc., Valo Health, LLC	INHIBITING USP19	Pending	Patent	Australia	PCT/US2020/031608	06-May-2020	
Valo Health, Inc. Valo Health, Inc., Valo Health, LLC	INHIBITING USP19 INHIBITING USP19	Pending Pending	Patent Patent	Canada China	PCT/US2020/031608 PCT/US2020/031608	06-May-2020 06-May-2020	
Valo Health, Inc., Valo Health, LLC	INHIBITING USP19	Pending	Patent	European Patent Office (EPO)	PCT/US2020/031608	06-May-2020	
Valo Health, Inc., Valo Health, LLC Valo Health, Inc., Valo Health, LLC	INHIBITING USP19 INHIBITING USP19	Pending Pending	Patent Patent	Japan United States of America	PCT/US2020/031608 PCT/US2020/031608	06-May-2020 06-May-2020	
Valo Health, Inc., Valo Health, LLC	INHIBITING USP19	Pending	Patent	Hong Kong	62022059951.3	09-Sep-2022	
Valo Health, Inc. Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending Pending	Patent Patent	European Patent Office (EPO) Hong Kong	PCT/US2017/050956 19128727.5	11-Sep-2017 11-Sep-2017	
Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending	Patent	Canada	PCT/US2017/050956	11-Sep-2017	
Valo Health, Inc. Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Granted Pending	Patent Patent	China India	PCT/US2017/050956 PCT/US2017/050956	11-Sep-2017 ZL201780068713.3 11-Sep-2017	05-May-2023
Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Granted	Patent	Japan	PCT/US2017/050956	11-Sep-2017 7086942	10-Jun-2022
Valo Health, Inc. Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending Granted	Patent Patent	Korea (South) United States of America	PCT/US2017/050956 PCT/US2017/050956	11-Sep-2017 11-Sep-2017 10,800,773	13-Oct-2020
Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Granted	Patent	United States of America	16/998,660	20-Aug-2020 11,548,886	10-Jan-2023
Valo Health, Inc. Valo Health, Inc.	MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending Granted	Patent Patent	United States of America European Patent Office (EPO)	17/959,064 P CT/US2017/050964	03-Oct-2022 11-Sep-2017 3509588	07-Jun-2023
Valo Health, Inc.	BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending	Patent	Hong Kong	19128730.9	11-Sep-2017	5, Juli 2023
Valo Health, Inc. Valo Health, Inc.	BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending Pending	Patent Patent	Canada China	PCT/US2017/050964 PCT/US2017/050964	11-Sep-2017 11-Sep-2017	
Valo Health, Inc.	BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Pending	Patent	India	PCT/US2017/050964	11-Sep-2017	
Valo Health, Inc. Valo Health, Inc.	BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Granted Pending	Patent Patent	Japan Korea (South)	PCT/US2017/050964 PCT/US2017/050964	11-Sep-2017 7065081 11-Sep-2017	27-Apr-2022
Valo Health, Inc.	BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS	Granted	Patent	United States of America	PCT/US2017/050964	11-Sep-2017 10,865,201	15-Dec-2020
Valo Health, Inc.	BICYCLIC COMPOUNDS USEFUL AS GPR12D MODULATORS	Pending	Patent	United States of America United States of America	17/121,165	14-Dec-2020 30-May-2003 7,577,553	10 4 2000
Valo Health, Inc. Valo Health, Inc.	METHOD AND APPARATUS FOR MOLECULAR MECHANICS ANALYSIS OF MOLECULAR ESTIMATING THE ACCURACY OF MOLECULAR PROPERTY MODELS AND PREDICTION	S Granted	Patent Patent	United States of America	10/452,481 11/172,216	29-Jun-2005 7,194,359	18-Aug-2009 20-Mar-2007
Valo Health, Inc. Valo Health, Inc.	MÓLECULÁR PRÓPERTY MÓDELING USING RANKING MÓDELING BIÓLOGICÁL EFFECTS OF MÓLECULES USING MÓLECULÁR PRÓPERTY M	Granted	Patent Patent	United States of America United States of America	11/172,215 11/304,209	29-Jun-2005 7,702,467 14-Dec-2005 7,856,321	20-Apr-2010 21-Dec-2010
Valo Health, Inc.	PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMI		Patent	United States of America	63/394,110	01-Aug-2022	21-060-2010
	.N: A MICROPHYSIOLÓGICAL PLATFORM WITH EMBEDDED ELECTRODES FOR 3D TISSUI .N: A MICROPHYSIOLÓGICAL PLATFORM WITH EMBEDDED ELECTRODES FOR 3D TISSUI		Patent Patent	Australia Canada	PCT/US2020/017195 PCT/US2020/017195	07-Feb-2020 07-Feb-2020	
	IN A MICROPHYSIOLOGICAL PLATFORM WITH EMBEDDED ELECTRODES FOR 3D TISSUI		Patent	European Patent Office (EPÖ)	PCT/US2020/017195	07-Feb-2020	
	IN A MICROPHYSIOLOGICAL PLATFORM WITH EMBEDDED ELECTRODES FOR 3D TISSUI		Patent Patent	Japan Korea (South)	PCT/US2020/017195 PCT/US2020/017195	07-Feb-2020 07-Feb-2020	
Milica Radisic, Valo Health, Inc., ZHANG BOYA	.N: A MICROPHYSIOLOGICAL PLATFORM WITH EMBEDDED ELECTRODES FOR 3D TISSUI .N: A MICROPHYSIOLOGICAL PLATFORM WITH EMBEDDED ELECTRODES FOR 3D TISSUI	CPending	Patent	United States of America	PCT/US2020/017195	07-Feb-2020	
Valo Health, Inc. Valo Health, Inc.	ARTIFICIAL SKELETAL MUSCLE TISSUE	Pending	Patent	United States of America	16/952,267	19-Nov-2020 03-Feb-2021	
Valo Health, Inc. Valo Health, Inc.	INTEGRATED SYSTEM FOR 3D TISSUE CULTURE INVERTIBLE MODELS OF CARDIAC FUNCTION	Pending Pending	Patent Patent	United States of America United States of America	PCT/US2021/016317 63/482,630	03-Feb-2021 01-Feb-2023	
Valo Health, Inc.	SYSTEM AND METHODS FOR PROCESSING OF FUNCTIONAL RESPONSE WAVEFORM:	S Pending	Patent	United States of America	63/457,574	06-Apr-2023	
Valo Health, Inc. Valo Health, Inc.	SPECTRAL ENCODING OF TISSUE BEHAVIOR SYSTEMS AND METHODS FOR DETECTING SPONTANEOUS TISSUE CONTRACTIONS	Pending Pending	Patent Patent	United States of America United States of America	63/429,797 63/466,105	02-Dec-2022 12-May-2023	
Valo Health, Inc.	ARTIFICIAL SKELETAL MUSCLE TISSUE	Pending	Patent	World Intellectual Property Org. (WIPO)	PCT/US2023/011874	30-Jan-2023	
Valo Health, Inc. Valo Health, Inc.	HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF	Pending Pending	Patent Patent	United States of America World Intellectual Property Org. (WIPO)	63/423,093 PCT/US2022/048911	04-Nov-2022 04-Nov-2022	
Valo Health, Inc.	TRICYCLIC PHTHALAZINONE PARP INHIBITORS AND METHODS OF USE	Pending	Patent	United States of America	63/350,366	08-Jun-2022	
Valo Health, Inc. Valo Health, Inc.	INHIBITORS OF HDAC11 BIOMARKER COMBINATIONS FOR PROGNOSIS AND MANAGEMENT OF DIABETIC RE	Pending TIPending	Patent Patent	United States of America United States of America	63/422,218 63/401,465	03-Nov-2022 26-Aug-2022	
Valo Health, Inc.	SELECTIVE INHIBITORS OF PDE1C AND USES THEREOF	Pending	Patent	United States of America	63/417,904	20-Oct-2022	
Valo Health, Inc. Valo Health, Inc.	SELECTIVE FIASMA TREATMENT SYSTEM AND METHOD FOR PREDICTING AND OPTIMIZING CLINICAL TRIAL OUTCON	Pending 1E:Pending	Patent Patent	United States of America United States of America	63/482,827 63/429,775	02-Feb-2023 02-Dec-2022	

Owners	Record name	Status	Module	Country	Classes	Application number Ap	pplication Date Registration/Grant Reg.	/ Grant date
Valo Health, Inc.	BIOWIRE	Registered	Trademark	United States of America	42	88303956	15-May-2019 6486701	14-Sep-2021
Valo Health, Inc.	NUMERATE	Registered	Trademark	United States of America	42	77621344	25-Nov-2008 3660448	28-Jul-2009
Valo Health, LLC	VALO (CIRCLE)	Pending	Trademark		1, 5, 9, 42	88945829	03-Jun-2020	20741 2003
Valo Health, LLC	VALO (CIRCLE)	Registered	Trademark	World Intellectual Property Org. (WIPO)	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570668	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Pending	Trademark		1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570668	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Pending	Trademark	Canada	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570668	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Registered	Trademark		1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570668	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Pending	Trademark		1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570668	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Registered	Trademark	European Union Intellectual Property Office (EU		A0102801	03-Dec-2020 1570668	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Registered	Trademark	United Kingdom	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570668	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Registered	Trademark	Israel	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570668	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Pending	Trademark	Japan	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570668	03-Dec-2020
Valo Health, LLC	VALO (CIRCLE)	Registered	Trademark	Singapore	1, 5, 9, 36, 42	A0102801	03-Dec-2020 1570668	03-Dec-2020
Valo Health, LLC	VALO (COLOR)	Pending	Trademark		1, 5, 9, 36, 42	88945981	03-Jun-2020	03-DEC-2020
Valo Health, LLC	VALO DATA GRAVITY	Registered	Trademark	World Intellectual Property Org. (WIPO)	42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Pending	Trademark		42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Pending	Trademark		42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Registered	Trademark		42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Registered	Trademark	China	42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Registered	Trademark	European Union Intellectual Property Office (EU		A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Registered	Trademark	United Kingdom	42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Registered	Trademark	Israel	42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Registered	Trademark	Japan	42	A0106489	15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC	VALO DATA GRAVITY	Pending	Trademark	Japan Singapore	42	A0106489 A0106489	15-Mar-2021 1610163 15-Mar-2021 1610163	15-Mar-2021
Valo Health, LLC					1, 5, 9, 42	88945793	03-Jun-2021 1610165	T2-Mai-505T
Valo Health, LLC Valo Health, LLC	VALO HEALTH VALO HEALTH	Pending	Trademark Trademark		1, 5, 9, 42	88945793 A0102800	03-Jun-2020 03-Dec-2020 1570709	03-Dec-2020
		Registered		World Intellectual Property Org. (WIPO)	1, 5, 9, 36, 42	A0102800 A0102800	03-Dec-2020 1570709 03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC Valo Health, LLC	VALO HEALTH	Pending	Trademark	Australia Canada		A0102800 A0102800		
	VALO HEALTH	Pending	Trademark		1, 5, 9, 36, 42		03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Registered	Trademark	Switzerland	1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Pending	Trademark	China	1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Registered	Trademark	European Union Intellectual Property Office (EU		A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Registered	Trademark	United Kingdom	1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Registered	Trademark		1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Registered	Trademark		1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO HEALTH	Registered	Trademark		1, 5, 9, 36, 42	A0102800	03-Dec-2020 1570709	03-Dec-2020
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Pending	Trademark		41	90181491	15-Sep-2020	
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark		41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Pending	Trademark		41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Pending	Trademark		41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark		41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark	China	41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark	European Union Intellectual Property Office (EU		A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark	United Kingdom	41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark		41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark		41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO OPAL COMPUTATIONAL PLATFORM	Registered	Trademark	Singapore	41	A0106488	15-Mar-2021 1610069	15-Mar-2021
Valo Health, LLC	VALO	Pending	Trademark	United States of America	1, 5, 9, 42	88945779	03-Jun-2020	
Valo Health, LLC	VALO	Registered	Trademark	World Intellectual Property Org. (WIPO)	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	Australia	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	Canada	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark		1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark		1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	European Union Intellectual Property Office (EU		A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	United Kingdom	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	Israel	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	Japan	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020
Valo Health, LLC	VALO	Registered	Trademark	Singapore	1, 5, 9, 36, 42	A0102797	03-Dec-2020 1570555	03-Dec-2020

EXHIBIT C

Mask Works

<u>Description</u>

Registration/ Application Number Registration/ Application Date

None

ACTIVE\900438463.2

RECORDED: 07/05/2023